Sell-side analysts are offering a consensus “Buy” rating on shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 1.80. Based on a recent trade, the shares are hovering around $4.01 which, according to analysts, yield significant upside potential to the $6.46 consensus target price.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) shares typically trade an average volume of 965.04 and institutions hold 74.20% of the total shares.
We see here that the stock is 19.38% away from the 20-Day Simple Moving Average. Their 50-Day Simple Moving Average is a difference of 16.55% from current levels. Further back, their 200-Day Simple Moving Average is -19.57% difference from today’s price. Currently, the stock is 4.70% from its 50-Day High and 30.19% from the 50-day low.
Pacific Biosciences of California, Inc. (NASDAQ:PACB)‘s stock has performed at 5.53%. Breaking that down further, it has performed 24.15% for the week, 15.23% for the month, 1.78% over the last quarter, -16.11% for the past half-year and -48.26% for this last year.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 1.60. This is according to all covering research brokerage firms taken into consideration by First Call. The consensus price target of $70.77 also implies significant upside from the current price of $53.50.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s shares may have a significant upside to the consensus target of 70.77, but how has it been performing relative to the market? The stock’s price is 53.50 and their relative strength index (RSI) stands at 73.26. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares are moving 9.54% trading at $53.50 today.